Loading
The progesterone receptor is the hormone receptor that, alongside the oestrogen receptor, marks breast cancers likely to respond to hormone therapy, and it is the target of the progestins megestrol and medroxyprogesterone used in endometrial and breast cancer.
The progesterone receptor (PR, gene PGR) is a nuclear receptor whose expression is switched on by oestrogen signalling, so PR positivity in a breast cancer indicates an intact, functioning oestrogen receptor pathway and a better response to endocrine therapy; it is reported with ER and HER2 on every breast cancer pathology report. Progestins such as megestrol acetate and medroxyprogesterone act through the receptor and are used as hormonal treatment for advanced endometrial cancer and as later-line therapy in hormone receptor-positive breast cancer, and progestin-containing intrauterine systems are used for fertility-sparing treatment of early endometrial cancer.
In plain words · The progesterone receptor is the hormone receptor that, alongside the oestrogen receptor, marks breast cancers likely to respond to hormone therapy, and it is the target of the progestins megestrol and medroxyprogesterone used in endometrial and breast cancer.
The progesterone receptor is the hormone receptor that, alongside the oestrogen receptor, marks breast cancers likely to respond to hormone therapy, and it is the target of the progestins megestrol and medroxyprogesterone used in endometrial and breast cancer.
PGR encodes two isoforms, PR-A and PR-B, from alternative promoters; the receptor binds progesterone, dimerises and regulates transcription at progesterone response elements, and it cross-talks with the oestrogen receptor at shared chromatin sites.
No product in this corpus aims at Progesterone receptor (PGR) yet. Drugs cut off the hormone supply, block the receptor so the hormone cannot bind, or send the receptor to the cell's waste disposal.
Tumour-associated overexpression or amplification: 1 of 1 label readouts filed under it score protein level or gene copies (PR status (progesterone receptor by IHC)), so the medicines rely on the tumour carrying more of it than normal tissue. HPA PGR: RNA group enriched (cervix 60 nTPM, endometrium 1 97 nTPM, fallopian tube 32 nTPM); high antibody staining in 4 normal tissues; highest cancer staining endometrial cancer (3 of 11 high). Distribution: 2 cancer families in the corpus carry a prevalence row, label threshold or catalogue link for it (Breast cancer (all types), Endometrial cancer); Open Targets associates it with 4 specific cancer types at or above 0.5 (breast cancer, leiomyoma, uterine corpus leiomyoma, atypical endometrial hyperplasia). (Rule 3 of scripts/fetch-target-specificity.ts.)
Sources: PR status (progesterone receptor by IHC) label threshold; Human Protein Atlas PGR tissue; Human Protein Atlas PGR pathology; Open Targets ENSG00000082175 associations
First described 1987. Earliest sequence paper UniProt cites for the protein: Misrahi et al, Biochem. Biophys. Res. Commun, 1987, "Complete amino acid sequence of the human progesterone receptor deduced from cloned cDNA". Source.
What a pathology or genomic report can say about this target, each with the thresholds approvals use.
PGR encodes two isoforms, PR-A and PR-B, from alternative promoters; the receptor binds progesterone, dimerises and regulates transcription at progesterone response elements, and it cross-talks with the oestrogen receptor at shared chromatin sites. In breast cancer PR expression is a marker of ER activity and of luminal A biology; loss of PR in an ER-positive tumour predicts a poorer response to endocrine therapy. In the endometrium progesterone opposes oestrogen-driven proliferation, which is why unopposed oestrogen causes endometrial cancer and progestins treat it.
RNA: group enriched (cervix 60 nTPM, endometrium 1 97 nTPM, fallopian tube 32 nTPM, smooth muscle 73 nTPM), detected in many normal tissues.
Medium: Breast, Efferent ducts, Nasopharynx, Testis.
RNA group enriched: Breast Invasive Carcinoma 21 pTPM, Uterine Corpus Endometrial Carcinoma 16 pTPM.
Medium only: lung cancer.
HPA PGR tissue · HPA PGR pathology · HPA protein class: FDA approved drug targets
Human Protein Atlas version 25.1, antibody staining at reliability approved, enhanced or supported; used under CC BY-SA 3.0. Staining counts are patients per level in the atlas cohort, not population prevalence.
| Cancer | Prevalence | Measure | Note | Source |
|---|---|---|---|---|
| HR-positive / HER2-negative breast cancer | about 65-70% | Progesterone receptor-positive by immunohistochemistry | cancer.org |
Approximate, population-level figures; the measure column says what was counted. Ranges show the midpoint as a bar.
Query for this target: (TITLE:"Progesterone receptor" OR ABSTRACT:"Progesterone receptor" OR TITLE:"PGR" OR ABSTRACT:"PGR") AND (cancer OR tumor OR tumour OR oncology OR carcinoma OR lymphoma OR leukemia OR leukaemia OR myeloma OR sarcoma OR melanoma OR glioma). Results are unfiltered search hits about Progesterone receptor (PGR), not a curated reading list.
Shares Progestins (megestrol acetate, medroxyprogesterone, levonorgestrel IUD), Endometrial cancer.
Shares Progestins (megestrol acetate, medroxyprogesterone, levonorgestrel IUD), Endometrial cancer.
Shares Progestins (megestrol acetate, medroxyprogesterone, levonorgestrel IUD), Endometrial cancer.
Shares PR status (progesterone receptor by IHC), Estrogen receptor (ERα), Immunohistochemistry (IHC), Endometrial cancer.
Shares Progestins (megestrol acetate, medroxyprogesterone, levonorgestrel IUD), Endometrial cancer.
Shares PR status (progesterone receptor by IHC), Immunohistochemistry (IHC), HR-positive / HER2-negative breast cancer.
Shares Estrogen receptor (ERα), HR-positive / HER2-negative breast cancer.
Shares Estrogen receptor (ERα), HR-positive / HER2-negative breast cancer.